DZ3239A1 - Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés - Google Patents

Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés

Info

Publication number
DZ3239A1
DZ3239A1 DZ013239A DZ013239A DZ3239A1 DZ 3239 A1 DZ3239 A1 DZ 3239A1 DZ 013239 A DZ013239 A DZ 013239A DZ 013239 A DZ013239 A DZ 013239A DZ 3239 A1 DZ3239 A1 DZ 3239A1
Authority
DZ
Algeria
Prior art keywords
dicarboxylates
diabetes
preparation
treatment
methods
Prior art date
Application number
DZ013239A
Other languages
English (en)
French (fr)
Inventor
Howard Yoshihisa Ando
Donald Eugene Butler
Gary Jay Dozeman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3239A1 publication Critical patent/DZ3239A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/305Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DZ013239A 2000-01-25 2001-01-11 Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés DZ3239A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17782300P 2000-01-25 2000-01-25
PCT/IB2001/000026 WO2001055078A1 (en) 2000-01-25 2001-01-11 Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith

Publications (1)

Publication Number Publication Date
DZ3239A1 true DZ3239A1 (fr) 2001-08-02

Family

ID=22650106

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013239A DZ3239A1 (fr) 2000-01-25 2001-01-11 Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés

Country Status (39)

Country Link
EP (1) EP1259474B1 (enExample)
JP (1) JP4750995B2 (enExample)
KR (1) KR20020073182A (enExample)
CN (1) CN1395555A (enExample)
AP (1) AP2002002587A0 (enExample)
AR (1) AR029436A1 (enExample)
AT (1) ATE431326T1 (enExample)
AU (1) AU2214001A (enExample)
BG (1) BG106851A (enExample)
BR (1) BR0107763A (enExample)
CA (1) CA2397960C (enExample)
CO (1) CO5261537A1 (enExample)
CZ (1) CZ20022474A3 (enExample)
DE (1) DE60138686D1 (enExample)
DK (1) DK1259474T3 (enExample)
DZ (1) DZ3239A1 (enExample)
EA (1) EA004862B1 (enExample)
EE (1) EE200200404A (enExample)
ES (1) ES2324281T3 (enExample)
GE (1) GEP20053428B (enExample)
GT (1) GT200100015A (enExample)
HN (1) HN2001000011A (enExample)
HU (1) HUP0204422A3 (enExample)
IL (1) IL150541A0 (enExample)
IS (1) IS6442A (enExample)
MA (1) MA26867A1 (enExample)
MX (1) MXPA02007223A (enExample)
NO (1) NO20023526L (enExample)
NZ (1) NZ519550A (enExample)
OA (1) OA12166A (enExample)
PA (1) PA8510601A1 (enExample)
PE (1) PE20011064A1 (enExample)
PL (1) PL357076A1 (enExample)
SK (1) SK10622002A3 (enExample)
SV (1) SV2002000290A (enExample)
TN (1) TNSN01013A1 (enExample)
UY (1) UY26550A1 (enExample)
WO (1) WO2001055078A1 (enExample)
ZA (1) ZA200205880B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481962A1 (en) * 1997-12-12 2004-12-01 Warner-Lambert Company LLC New cholesterolemia-lowering carboxyalkylether compound
WO2004017952A1 (en) * 2002-08-22 2004-03-04 Warner-Lambert Company Llc Method of treating osteoarthritis
CN101163668A (zh) * 2005-04-19 2008-04-16 卫材R&D管理有限公司 双[(2s)-3-[3-(2s)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸]钙及其中间体
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
WO2016077832A2 (en) * 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
CA3059073A1 (en) * 2017-04-18 2018-10-25 Daniela Carmen Oniciu Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
CN113396138A (zh) * 2018-10-18 2021-09-14 燿石治疗公司 吉卡宾、其药学上可接受的盐、其组合物和其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
JP2003520835A (ja) 2003-07-08
UY26550A1 (es) 2001-08-27
CA2397960C (en) 2008-09-09
GT200100015A (es) 2001-10-19
EP1259474A1 (en) 2002-11-27
WO2001055078A1 (en) 2001-08-02
ES2324281T3 (es) 2009-08-04
NO20023526D0 (no) 2002-07-24
DE60138686D1 (de) 2009-06-25
MA26867A1 (fr) 2004-12-20
SK10622002A3 (sk) 2003-07-01
AU2214001A (en) 2001-08-07
EA004862B1 (ru) 2004-08-26
GEP20053428B (en) 2005-01-25
MXPA02007223A (es) 2002-11-29
PL357076A1 (en) 2004-07-12
EA200200641A1 (ru) 2002-12-26
KR20020073182A (ko) 2002-09-19
JP4750995B2 (ja) 2011-08-17
EE200200404A (et) 2003-10-15
PE20011064A1 (es) 2001-10-22
CZ20022474A3 (cs) 2003-06-18
EP1259474B1 (en) 2009-05-13
ZA200205880B (en) 2003-07-23
ATE431326T1 (de) 2009-05-15
SV2002000290A (es) 2002-07-16
IS6442A (is) 2002-06-25
IL150541A0 (en) 2003-02-12
CA2397960A1 (en) 2001-08-02
PA8510601A1 (es) 2002-08-26
CO5261537A1 (es) 2003-03-31
HUP0204422A2 (en) 2003-05-28
NZ519550A (en) 2003-11-28
BR0107763A (pt) 2002-11-12
DK1259474T3 (da) 2009-07-20
AP2002002587A0 (en) 2002-09-30
AR029436A1 (es) 2003-06-25
BG106851A (en) 2003-01-31
CN1395555A (zh) 2003-02-05
TNSN01013A1 (fr) 2005-11-10
HUP0204422A3 (en) 2003-08-28
NO20023526L (no) 2002-08-27
HN2001000011A (es) 2001-06-13
OA12166A (en) 2003-11-07

Similar Documents

Publication Publication Date Title
MA26992A1 (fr) Derives de phenethanolamine pour le traitement des maladies respiratoires
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DK0817770T3 (da) Nonpeptider som tachykininantagonister
DE59711321D1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
EP1357908A4 (en) "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
FIU20060389U0 (fi) Luusairauksien hoito
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
MA26951A1 (fr) Derives de pyrazole pour le traitement de maladies virales
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE323680T1 (de) 7-arylsulfonamid-2,3,4,5-tetrahydro-1h- benzo¬däazepine mit 5-ht6 rezeptor affinität zur behandlung von zentralnervensystemerkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EP1126850A4 (en) TREATMENT OF RETINAL DISEASES
DZ3239A1 (fr) Ether-dicarboxylates de calcium, procedes pour leur preparation et traitement de maladies vasculaires et du diabete avec ces composés
EP1429775A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
ATE296635T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk